anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 219,181-219,210
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

219,181-219,210 of 303,780

filter-aware
23
The slide uses a process-flow visual to connect capabilities to specific solutions and products.Bigbear AI | Investor Presentation Deck | 29 slides · BigBear.ai
Pitch deck Investor relations 1 hit
24
Bigbear AI | Investor Presentation Deck | 29 slidesBigbear AI | Investor Presentation Deck | 29 slides · BigBear.ai
Pitch deck Investor relations 1 hit
25
Includes a process diagram showing inputs (models, schedules, ERP), constraints, and outputs (maps, timelines, charts).Bigbear AI | Investor Presentation Deck | 29 slides · BigBear.ai
Pitch deck Investor relations 1 hit
26
Standard financial reconciliation table showing adjustments for non-cash and non-recurring items.Bigbear AI | Investor Presentation Deck | 29 slides · BigBear.ai
Pitch deck Investor relations 1 hit
27
The table shows adjustments for non-recurring items like restructuring charges, transaction expenses, and goodwill impairment.Bigbear AI | Investor Presentation Deck | 29 slides · BigBear.ai
Pitch deck Investor relations 1 hit
29
Bigbear AI | Investor Presentation Deck | 29 slidesBigbear AI | Investor Presentation Deck | 29 slides · BigBear.ai
Pitch deck Investor relations 1 hit
01
Slide 1
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
02
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
03
The slide uses a linked-circle diagram to represent the interconnected nature of the company's value proposition.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The slide uses a grid layout to display 8 team members with headshots, names, titles, and logos of past companies.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a visual comparison between healthy cells (alkaline) and cancer cells (acidic) to demonstrate the selective binding mechanism.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a horizontal bar chart integrated into a table to represent clinical trial phases.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
09
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
10
The slide uses a structured list format to define the target market and unmet medical need.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
11
The slide uses a waterfall plot for response and a spider plot for longitudinal tumor burden change.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
13
Includes clinical trial design details (dosing regimens, patient counts, endpoints).BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
14
The slide uses a decision tree/process flow to map patient cohorts to clinical outcomes and subsequent trial progression.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
16
Includes detailed footnotes for data sources and medical abbreviations.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
17
The chart is a classic waterfall plot used in oncology to show tumor shrinkage/growth.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Traction1 hit
18
The slide uses a process-oriented layout to describe clinical trial progression.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Traction1 hit
24
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
25
The slide uses a combination of high-level market statistics and specific clinical benchmarks to define the target opportunity.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
26
The chart highlights a specific patient case with a partial response (PR) and notes a suboptimal dose case.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
27
Uses a 2x2 grid of metrics to frame the problem space.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
29
The slide uses a funnel-like logic to narrow down from total prevalence to a specific addressable patient population for a 2L+ therapy.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
30
The slide uses a table to present clinical trial outcomes (PR/CR) and safety data.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
31
The slide outlines patient enrollment targets and treatment protocols for specific refractory patient populations.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
33
BA3021 Ozuriftamab VedotinBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
34
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit